GlassScriptPhysician profile
Travis B Henderson
NPI 1558343061
$5,992.57
in general payments reported to CMS, 2019-2025
24 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $142 · 2021: $1,260 · 2022: $1,084 · 2023: $896 · 2024: $906 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $995.11 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $723.77 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $550.23 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.17 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $461.29 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $456.85 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $451.16 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $299.93 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $280.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $252.05 | 2019-2024 | Capvaxive, Vaxneuvance, Gardasil |
| Sanofi-Aventis U.S. LLC | $208.02 | 2019-2022 | |
| Pfizer INC. | $195.96 | 2019-2021 | |
| Exact Sciences Corporation | $155.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $100.14 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $93.71 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77.88 | 2022-2025 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $42.75 | 2022 | |
| Smith+Nephew, INC. | $33.85 | 2023 | Grafix |
| Vertex Pharmaceuticals Incorporated | $22.84 | 2025 | |
| Allergan, INC. | $17.07 | 2020 | |
| Edwards Lifesciences Corporation | $16.33 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2025 | Uptravi, Opsumit |
| Medtronic, INC. | $15.01 | 2025 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.